Files in this Data Supplement:

• Affiliations - (Word) (23.5KB) Statistical Support Team and ASCOT Substudy Committee affiliations.
• Supplemental Materials - (Word) (32 KB)
• Table I - (Word) (52 KB) Percentage of time on blood pressure lowering medication by treatment group and study period for the patients recruited into the CAFE study.
• Table II - (Word) (47.5 KB) Hemodynamic, pulse wave analysis and pulse wave velocity measurements (mean, 95%CI) in a sub-group of CAFE patients (atenolol n= 53, amlodipine n= 61) measured at their final study visit. Augmentation (ΔP); difference between maximal pressure and pressure at the first peak/shoulder (T1), AIx; aortic augmentation index - proportion of the central pressure wave height attributable augmentation (ΔP)(AIx =(ΔP/PP)x100), P1 Height; difference between the minimum pressure and the pressure at the first peak/shoulder (T1), PWVCF; carotid-femoral pulse wave velocity.
• Figure - CI093185.OLfig1.ppt (PowerPoint) (64.5 KB) PWA parameters (mean, 95%CI) with time for patients randomised to receive atenolol ± thiazide (solid lines) or amlodipine ± perindopril-based therapy (broken lines). AUC; area under the curve (mean, 95%CI). A: pulse pressure amplification (brachial pulse pressure: central aortic pulse pressure), B: outgoing pressure wave (P1 Height), C: augmentation (ΔP, reflected pressure wave), D: augmentation index (proportion of the central pressure wave attributable augmentation; AIx =(ΔP/PP)x100). AUC; area under the curve (mean, 95%CI). Numbers below abscissa represent the number of patients seen at each time point. In both panels, time represents the duration from randomization into ASCOT to patient follow-up visit at which tonometry measurement was made in the CAFE study.